Austrian Biotech’s Investigational Phase II Drug Receives Compassionate Use Approval for COVID-19 ARDS

About 20% of those hospitalized with COVID-19 suffer from acute respiratory distress syndrome (ARDS), a potentially life-threatening complication of the infection with SARS-CoV-2. Consequently, an Austrian biotech has received compassionate use approval from the...

European Immuno-Oncology Collaboration

As reported in Associated Press, the National Center for Tumor Diseases (NCT) and NEC Laboratories Europe GmbH have announced a collaboration to improve the in silico prediction of immunotherapy response in malignant melanoma. Cancer immunotherapy, e.g. by Checkpoint...

Pin It on Pinterest